SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 59 of 94
Word Count: 1381
Character Count: 8542

Document Content:

applicable award agreement, a participant generally will have the rights and privileges of a stockholder as to such restricted shares, including, without limitation, the right to vote such restricted shares and the right to receive cash dividends, if applicable. Equitable Adjustments any change is made in the Shares subject to the 2024 Plan, or subject to any stock award, without the receipt of consideration (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by us), the 2024 Plan will be appropriately adjusted in the class(es) and maximum number of securities subject to the 2024 Plan and the outstanding awards will be appropriately adjusted in the class(es) and number of securities and price per Share subject to such outstanding awards. Change in Control

the event of (x) a sale, lease or other disposition of all or substantially all of our assets, (y) a merger or consolidation in which
we are not the surviving corporation or (z) a reverse merger in which we are the surviving corporation but the Shares outstanding immediately
preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise,
all options outstanding under the 2024 Plan will be treated in the manner described in the definitive transaction agreement approved
by the Board, which agreement need not treat all options outstanding in an identical manner. Such treatment may include, without limitation,
one or more of the following with respect to each outstanding option outstanding under the 2024 Plan: (i) continuation of the option
by the us (if we are the surviving entity in the transaction), (ii) assumption of the option by the surviving corporation or its parent
in a manner that complies with applicable law and tax provisions, (iii) substitution by the surviving corporation or its parent of a
new option or stock purchase right for the option in a manner than complies with applicable law and tax provisions, (iv) cancellation
of the option and a payment of the spread (unless such option is underwater, in which case it may be cancelled for no payment), (v) cancellation
of the option without the payment of any consideration; provided that the optionholder will be notified of such treatment and given an
opportunity to exercise the option to the extent vested, (vi) suspension of the optionholder’s right to exercise the option during
a limited period of time preceding the closing if such suspension is administratively necessary to permit the closing of the transaction,
and/or (vii) termination of any right of an optionholder has to exercise the option prior to vesting in the shares subject to the option,
such that at or following the closing of the transaction, the option may only be exercised to the extent it is vested, in each case,
as determined by the Board.

Term

The
2024 Plan became effective upon approval by the Board on August 7, 2024, but was terminated in connection with our adoption of the 2026
Plan, as discussed below. Awards made under the 2024 Plan will remain subject to the terms and conditions of such plan until they vest,
expire, or are forfeited. Following the termination of the 2024 Plan, no further awards may be made under the 2024 Plan.

Summary
of Material Terms of the 2026 Plan

The
following is a summary of the material features of the BioVentrix, Inc. 2026 Equity Incentive Plan (the “2026 Plan”), which
was adopted by the Board and our stockholders on [________].

Eligibility

The
Administrator may grant awards to any director, employee or consultant of the Company or its subsidiaries. Only employees are eligible
to receive incentive stock options.

Administration

The
2026 Plan will be administered by the Board of Directors (the “Board”) or one more committees or subcommittees of the Board,
which will be comprised, unless otherwise determined by the Board, solely of not less than two members who will be non-employee directors
(a “Committee”), or any officer that has been delegated administrative authority pursuant to the 2026 Plan for the duration
such delegation is in effect (collectively, the “Administrator”). The Administrator, which initially will be the Board with
respect to awards to non-employee directors and the Compensation Committee of our Board with respect to other participants. The Administrator
will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the
administration of the 2026 Plan, subject to the 2026 Plan’s express terms and conditions. The Administrator will also set the terms
and conditions of all awards under the 2026 Plan, including any vesting and vesting acceleration conditions.

Share
Reserve

The
maximum aggregate number of Shares that may be issued under the 2026 Plan is the sum of (A) 10% of the issued and outstanding shares
of the Company as of the closing of this offering, plus (B) an increase commencing on January 1, 2027,
and continuing annually on each anniversary thereof through and including January 1, 2035, equal to the lesser of (i) 3% of the Shares
issued and outstanding on the last day of the immediately preceding calendar year and (ii) such smaller number of Shares as determined
by the Board or the Committee.

Also,
20% of the issued and outstanding shares of the Company as of the closing of this offering may be
issued upon the exercise of incentive stock options.

Shares
issuable under the 2026 Plan may be authorized, but unissued, or reacquired shares. Shares underlying any awards under the 2026 Plan
that are settled in cash, forfeited, canceled, repurchased, held back upon exercise of an option or settlement of an award to cover the
exercise price or tax withholding satisfied without the issuance of stock or otherwise terminated (other than by exercise) will be added
back to the Shares available for issuance under the 2026 Plan, although Shares shall not again become available for issuance as incentive
stock options. Additionally, Shares issued as “substitute awards” (as defined in the 2026 Plan) will not count against the
2026 Plan’s share limit, except substitute awards that are incentive stock options will count against the incentive stock option
limit.

The
share reserve described herein may be subject to certain adjustments in the event of certain changes in our capitalization (see Equitable
Adjustments below).

Annual
Limitation on Awards to Non-Employee Directors

The
2026 Plan contains a limitation whereby the value of all awards under the 2026 Plan and all other cash compensation paid by us to any
non-employee director may not exceed $950,000 for the first calendar year a non-employee director is initially appointed to the Board,
and $700,000 in any other calendar year.

Types
of Awards

The
2026 Plan provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards,
dividend equivalent awards, and other stock- or cash-based awards (collectively, “awards”).

Stock
Options. The 2026 Plan permits the granting of both options intended to qualify as incentive stock options under Section 422 of the
Internal Revenue Code of 1986, as amended (the “Code”) and options that do not so qualify. Options granted under the 2026
Plan will be nonqualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options.
Incentive stock options may only be granted to employees of the Company and its subsidiaries. Nonqualified options may be granted to
any persons eligible to receive awards under the 2026 Plan.

The
exercise price of each option will be determined by the Administrator, but such exercise price may not be less than 100% of the fair
market value of one Share on the date of grant or, in the case of an incentive stock option granted to a 10% or greater stockholder,
110% of such Share’s fair market value. The term of each option will be set by the Administrator and may not exceed ten (10) years
from the date of grant (or five (5) years for an incentive stock option granted to a 10% or greater stockholder). The Administrator will
determine at what time or times each option may be exercised, including the ability to accelerate the vesting of such options.